Combinations of Maternal Serum Markers to Predict Preeclampsia, Small for Gestational Age, and Stillbirth: A Systematic Review

Journal of Obstetrics and Gynaecology Canada

Volumn 34, Issue 2, 2012, Pages 142-153

  Hui, Dini ^a   Okun, Nan ^b   Murphy, Kellie ^b   Kingdom, John ^b   Uleryk, Elizabeth ^c   Shah, Prakesh S ^d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Maternal serum screen; Preeclampsia; Small for gestational age; Stillbirth

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; BIOLOGICAL MARKER; ESTRIOL; INHIBIN; INHIBIN A; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ANEUPLOIDY; ARTICLE; COHORT ANALYSIS; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MATERNAL SERUM; OUTCOME ASSESSMENT; PREDICTION; PREECLAMPSIA; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SMALL FOR DATE INFANT; STILLBIRTH; SYSTEMATIC REVIEW; BLOOD; FEMALE; METHODOLOGY; NEURAL TUBE DEFECT; NEWBORN; PREGNANCY; PRENATAL DIAGNOSIS; REVIEW;

ALPHA-FETOPROTEINS; ANEUPLOIDY; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; ESTRIOL; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; INHIBINS; NEURAL TUBE DEFECTS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; STILLBIRTH;

EID: 84861809666     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)35157-X     Document Type: Article

References (34)

1. Yaron Y., Cherry M., Kramer R.L., O'Brien J.E., Hallak M., Johnson M.P., et al. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 1999, 181:968-974.
2. Aquilina J., Maplethorpe R., Ellis P., Harrington K. Correlation between second trimester maternal serum inhibin-A and human chorionic gonadotrophin for the prediction of preeclampsia. Placenta 2000, 21:487-492.
3. Wald N.J., Morris JK. Multiple marker second trimester serum screening for preeclampsia. J Med Screen 2001, 8:65-68.
4. Van Rijn M., Van Der Schouw Y.T., Hagenaars A.M., Visser G.H.A., Christiaens G.C.M.L. Adverse obstetric outcome in low- and high-risk pregnancies: predictive value of maternal serum screening. Obstet Gynecol 1999, 929-934.
5. Morris R.K., Cnossen J.S., Langejans M., Robson S.C., Kleijnen J., ter Riet G., et al. Serum screening with Down's syndrome markers to predict preeclampsia and small for gestational age: systematic review and meta-analysis. BMC Pregnancy Childbirth 2008, 8:33.
6. Morssink L.P., Kornman L.H., Hallahan T.W., Beekhuis J.R., De Wolf B.T.H.M., Mantingh A. Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn 1998, 18:147-152.
7. Androutsopoulos G., Gkogkos P., Papadopoulos V., Adonakis G., Tsapanos V., Vassilakos P., et al. Mid-trimester maternal serum markers in predicting adverse pregnancy outcome. Clin Exp Obstet Gynecol 2009, 36:237-240.
8. Wenstrom K.D., Owen J., Boots L.R., Dubard M.B. Elevated second trimester human chorionic gonadotropin levels in association with poor pregnancy outcome. Am J Obstet Gynecol 1994, 171:1038-1041.
9. Brown M.A., Lindheimer M.D., de Swiet M., Van Assche A., Moutquin J.M. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001, 20:IX-XIV.
10. McCowan L.M., Harding J.E., Stewart A.W. Customized birthweight centiles predict SGA pregnancies with perinatal morbidity. BJOG 2005, 112:1026-1033.
11. Whiting P., Rutjes A.W., Dinnes J., Reitsma J., Bossuyt P.M., Kleijnen J. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004, 8(iii):1-234.
12. Whiting P., Rutjes A.W., Reitsma J.B., Bossuyt P.M., Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 3:25.
13. Whiting P.F., Weswood M.E., Rutjes A.W., Reitsma J.B., Bossuyt P.M., Kleijnen J. Evaluation of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy studies. BMC Med Res Methodol 2006, 6:9.
14. Morssink L.P., Kornman L.H., Beekhuis J.R., De Wolf B.T.H.M., Mantingh A. Abnormal levels of maternal serum human chorionic gonadotropin and alpha fetoprotein in the second trimester: relation to fetal weight and preterm delivery. Prenat Diagn 1995, 15:1041-1046.
15. Milunsky A., Nebiolo L. Maternal serum triple analyte and screening and adverse pregnancy outcome. Fetal Diagn Ther 1996, 11:249-253.
16. Morssink L.P., Heringa M.P., Beekhuis J.R., De Wolf B.T.H.M., Mantingh A. The HELLP syndrome: its association with unexplained elevation of MSAFP and MShCG in the second trimester. Prenat Diagn 1997, 17:601-606.
17. Davey D.A., MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988, 158:892-898.
18. Spencer K. Second trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat Diagnosis 2000, 20:652-656.
19. Chandra S., Scott H., Dodds L., Watts C., Blight C., Van den Hof M. Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gynecol 2003, 189:775-781.
20. Dugoff L., Hobbins J.C., Malone F.D., Sullivan L., Canick J.A., Lambert-Messerlian G.M., et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005, 106:260-267.
21. Smith G.C.S., Shah I., Crossley J.A., Aitken D.A., Pell J.P., Nelson S.M., et al. Pregnancy associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol 2006, 107:161-166.
22. Kang J.H., Farina A., Park J.H., Kim S.H., Kim J.Y., Rizzo N., et al. Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity. Prenat Diagn 2008, 28:704-709.
23. Pihl K., Larsen T., Krebs L., Christiansen M. First trimester maternal serum PAPP-A, beta-hCG, and ADAM12 in the prediction of small-for-gestational-age fetuses. Prenat Diagn 2008, 28:1131-1135.
24. Pihl K., Sorensen T.L., Norgaard-Pedersen B., Larsen S.O., Nguyen T.H., Krebs L., et al. First trimester combined screening for Down syndrome: prediction of low birth weight, small for gestational age, and pre-term delivery in a cohort of non-selected women. Prenat Diagn 2008, 28:247-253.
25. Montanari L., Alfei A., Albonico G., Moratti R., Arossa A., Beneventi F., et al. The impact of first trimester serum free beta-human chorionic gonadotropin and pregnancy associated plasma protein A on the diagnosis of fetal growth restriction and small for gestation age infant. Fetal Diagn Ther 2009, 25:130-135.
26. Beekhuis J.R., Van Lith J.M.M., De Wolf B.T.H.M., Mantingh A. Increased maternal serum alpha-fetoprotein and human chorionic gonadotropin in compromised pregnancies other than for neural tube defects or Down Syndrome. Prenat Diagn 1992, 12:643-647.
27. Kuller J.A., Sellati L.E., Chescheir N.C., Helwick J.J., Lincoln-Boyea B., Boor-Smith C., et al. Outcome of pregnancies with elevation of both maternal serum alpha-fetoprotein and human chorionic gonadotropin. Am J Perinatol 1995, 12(2):93-97.
28. Deeks J.J., Altman DG. Diagnostic tests 4: likelihood ratios. BMJ 2004, 329:168-169.
29. Gagnon A., Wilson R.D., Audibert F., Allen V.M., Blight C., Brock J.A., et al. Society of Obstetricians and Gynaecologists of Canada Genetics Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. SOGC clinical Practice Guideline No. 217, October 2008. J Obstet Gynaecol Can 2008, 30:918-949.
30. Giguere Y., Charland M., Bujold E., Bernard N., Grenier S., Rousseau F., et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem 2009, 56:1-15.
31. Dugoff L. Society for Maternal-Fetal Medicine. First- and second- trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol 2010, 115:1052-1061.
32. Toal M., Chan C., Fallah S., Alkazaleh F., Chaddha V., Windrim R.C., et al. Usefulness of a placental profile in high-risk pregnancies. Am J Obstet Gynecol 2007, 196(363):1-7.
33. Poon L.C., Stratieva V., Piras S., Piri S., Nicolaides K.H. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat Diagn 2010, 30:216-223.
34. Poon L.C.Y., Akolekar R., Lachmann R., Beta J., Nicolaides K.H. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol 2010, 35:662-670.